Welcome to our dedicated page for Haleon plc SEC filings (Ticker: HLN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Haleon plc's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Haleon plc's regulatory disclosures and financial reporting.
Haleon plc is starting a share buyback programme to repurchase its ordinary shares for up to an aggregate consideration of £500 million. The programme follows its 2025 preliminary full year results announcement and is aligned with its capital allocation priorities, including delivering attractive shareholder returns.
Haleon has signed an irrevocable agreement with HSBC Bank plc, which will independently decide the timing of purchases on the London Stock Exchange, CBoE Equities Europe, and Aquis, including during closed periods. The buyback begins immediately and will end no later than 19 August 2026.
Purchases before the 2026 Annual General Meeting will use the existing 2025 shareholder authority, and any later purchases will rely on authority sought at the 2026 AGM, if approved. All repurchased shares will be cancelled to reduce Haleon’s share capital, and there is no guarantee the full programme will be completed.
Haleon plc provided an update on its total voting rights and share capital. As at 28 February 2026, the company had 8,952,353,648 issued ordinary shares of £0.01 each, with 43,969,144 held as treasury shares. This leaves 8,908,384,504 ordinary shares carrying voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose interests or changes in interests under the FCA's Disclosure Guidance and Transparency Rules.
Haleon plc has made its preliminary full year results for the year ended 31 December 2025 available online and through the UK Financial Conduct Authority’s National Storage Mechanism. The statement can be accessed via the Haleon investor website and London Stock Exchange document link.
Reflecting strong free cash flow and organic operating profit growth, the Board is proposing a 2025 total dividend of 7.1p per ordinary share, a payout ratio of about 38% of 2025 adjusted earnings versus 37% in 2024. This includes a final dividend of 4.9p per share, subject to shareholder approval, with payment on 14 May 2026 to holders on the register as of 10 April 2026. The ex-dividend date is 9 April 2026 for ordinary shares and 10 April 2026 for ADSs, and DRIP elections are due by 24 April 2026. Haleon states it expects to grow its ordinary dividend at least in line with adjusted earnings.
A recorded results presentation by the CEO and CFO will be available from 7:00am GMT on 25 February 2026, followed by a Q&A call at 8:45am GMT with international dial-in access and a later archived webcast on the investor website.
Haleon plc reported routine share plan transactions by two senior executives under its Share Reward Plan. On 10 February 2026, General Counsel Adrian Morris acquired 31 ordinary shares at £3.956 as Partnership Shares and received 31 Matching Shares at no cost, for an aggregated volume of 62 shares. On the same date, President, Europe Jonathan Workman acquired 32 Partnership Shares at £3.956 and received 32 Matching Shares at no cost, an aggregated 64 shares. All transactions involved ordinary shares of £0.01 each, traded on the London Stock Exchange.
Wellington Management Group LLP and related entities report their ownership of Haleon plc common stock on an amended Schedule 13G. As of 12/31/2025, they beneficially own 443,046,686 shares, representing 4.97% of the class, with shared voting and dispositive power through investment adviser clients.
The securities are held in the ordinary course of business by Wellington-managed clients and are not held for the purpose of changing or influencing control of Haleon. No individual client is reported to hold more than five percent of the class.
Haleon plc has updated its share capital and voting rights information. As at 31 January 2026, the company has issued 8,952,353,648 ordinary shares of £0.01 each, of which 45,557,120 shares are held in treasury. This leaves 8,906,796,528 ordinary shares with voting rights.
Shareholders and others with notification obligations under the FCA's Disclosure Guidance and Transparency Rules are instructed to use the voting-rights figure as the denominator when assessing whether they must report their holdings or changes in their interest in Haleon.
Haleon plc filed a report noting an additional external role for its Chief Financial Officer. Dawn Allen, Haleon’s CFO, has been appointed Chair of the Audit & Risk Committee of ITV plc, effective 5 March 2026. She has already been serving as a Non-Executive Director of ITV and a member of its Audit & Risk Committee since 2 October 2023.
The update is described as a director declaration made in line with Listing Rule 6.4.9R(2). Haleon also reiterates that it is a global consumer health company with a portfolio of well-known brands including Advil, Centrum, Panadol, Sensodyne, Theraflu and Voltaren.
Haleon plc outlined an evolution of its operating model to support its “Win as One” strategy, aiming to drive growth, productivity and culture, with changes expected to be implemented by mid-2026. The company has created a new Chief Growth Officer role that will oversee Category, Marketing and Strategy functions, plus a new global Commercial Excellence team, and will lead the growth and innovation agenda together with R&D, Supply Chain and new Operating Units.
Haleon is also reorganising into six Operating Units, splitting the current EMEA & LatAm region into Latin America, Middle East and Africa, and Europe, and establishing India Subcontinent as its own unit separate from Asia Pacific, while North America remains unchanged. In addition, a new Chief Transformation Officer will coordinate transformation across business processes, the operating model and technology. The CGO, CTO and each Operating Unit President will join the Executive Committee and report to CEO Brian McNamara. Further detail is expected with the Preliminary Full Year Results scheduled for 25 February 2026.
Haleon plc reported routine share transactions by two senior executives under its Share Reward Plan. The company disclosed that on 5 January 2026, General Counsel Adrian Morris and Chief Marketing Officer Tamara Rogers, both classified as persons discharging managerial responsibilities (PDMRs), acquired ordinary shares in Haleon.
Each PDMR acquired 34 Partnership Shares in Haleon at a price of £3.71 per share and received an award of 34 Matching Shares at £0, giving an aggregated volume of 68 ordinary shares per person. The transactions took place on the London Stock Exchange and were reported in line with UK Market Abuse Regulation requirements.
Haleon plc reported its share count and voting rights as of 31 December 2025. The company had a total of 8,952,353,648 ordinary shares of £0.01 each in issue, of which 45,745,646 were held as treasury shares without voting rights.
After excluding treasury shares, the number of ordinary shares with voting rights was 8,906,608,002. Shareholders and others with disclosure obligations are asked to use this figure as the denominator when calculating whether they need to notify their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.